BDR Pharma launches Nilotinib to treat PH+ leukemia
PH+ Leukemia, encompassing Acute Lymphoblastic Leukemia (ALL) and Chronic Myeloid Leukemia (CML) are infrequent and complex types…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
BDR Pharma
How cloud utilisation can transform the pharma industry
Raheel Shah, director, BDR Pharma analyses how cloud computing in the pharma sector has evolved to address significant privacy,…
BDR Pharma launches generic Palbociclib for breast cancer treatment
The drug will be made available in three strengths i.e. – 125 mg, 100 mg and 75 mg capsules priced at Rs 3,150 for 75 mg; Rs 3,600…
BDR Pharma launches maiden generic to treat prostate cancer in India
The product will be available across India and shall be of 60 mg strength and available in two packs – 60 tablets and 120 tablets
By 2023, pharma industry is expected to be worth more than $1 trillion
As a part of Express Pharma’s January 2023 cover story, Raheel Shah, Director, BDR Pharma, shares his views below. The pharma…
Raw material prices affect margins of pharma drugs
Raheel Shah, Director, BDR Pharma, explains why pharma sector requires extraordinary precision and attention at every stage…
BDR Pharma partners with Varenyam Healthcare to launch Sugmadex in India
Sugmadex is a pioneer in anaesthesia drugs offering safe, rapid and complete reversal of shallow, moderate and deep neuromuscular…
Multiples private equity-led consortium invests Rs 6,850 million in BDR Pharma
The funds will be used by the company to build additional research and development capabilities in current and emerging areas,…
BDR Pharma launches anti-cancer drug Furmecil
Furmecil is an oral drug, indicated in adults for the treatment of advanced gastric cancer
Essential drugs’ price hike: The impact
Raheel Shah, Director, BDR Pharma, explains the pinch that the consumers will feel as a result of the price hike of over 800…